Table 3.
Relationship between Clinicopathological Parameters and Immunohistochemical Expression of Cox-2 and VEGF in the Esophageal Squamous Cell Carcinoma
| Cox-2 | VEGF | |||||
|---|---|---|---|---|---|---|
| Neg n (%) | Pos n (%) | p | Neg n (%) | Pos n (%) | p | |
| Gender (n=28) | NS | NS | ||||
| Male | 4 (14.29) | 19 (67.86) | 13 (46.43) | 10 (35.71) | ||
| Female | 1 (3.57) | 4 (14.29) | 2 (7.14) | 3 (10.29) | ||
| Age (n=28) | NS | NS | ||||
| ≥60 | 2 (7.14) | 14 (50.00) | 9 (32.14) | 7 (25.00) | ||
| <60 | 3 (10.71) | 9 (32.15) | 6 (21.43) | 6 (21.43) | ||
| Surgical margin (n=28) | NS | NS | ||||
| compromised | 0 (0.00) | 9 (32.10) | 1 (3.57) | (28.60) | ||
| Not compromised | 5 (17.90) | 14 (50.00) | 1 (3.57) | 18 (64.30) | ||
| Lymph node status (n=20) | NS | NS | ||||
| Positive | 0 (0.00) | 7 (35.00) | 1 (5.00) | (30.00) | ||
| Negative | 4 (20.00) | 9 (45.00) | 1 (5.00) | 12 (60.00) | ||
| Tumor differentiation (n=28) | NS | NS | ||||
| well-differentiated | 0 (0.00) | 5 (17.85) | 1 (3.57) | 3 (10.72) | ||
| moderatelydifferentiated | 5 (17.86) | 14 (50.00) | 2 (7.14) | 17 (60.71) | ||
| undifferentiated | 0 (0.00) | 4 (14.30) | 0 (0.00) | 5 (17.86) | ||
| Follow-up (n=28) | ||||||
| Live without disease | 5 (21.74) | 4 (17.39) | <0.05 | 3 (10.71) | 6 (21.42) | <0.05 |
| Live with disease | 2 (7.14) | 1 (3.57) | 3 (10.71) | 0 (0.00) | ||
| Death by cancer | 8 (34.78) | 6 (26.09) | 5 (17.85) | 9 (32.14) | ||
| Lost | 2 (7.14) | 0 (0.00) | 2 (7.14) | 0 (0.00) | ||
Negative expression. Cox-2 has a better prognosis; Positive VEGF has a worst prognosis; NS, notsignificant.